Reaction

Chapped Lips reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,289 reports · 95 co-occurring drugs

As of the last recalculation, Chapped Lips appears in 4,289 FAERS reports alongside 95 co-occurring drug terms. The strongest observed disproportionality signal is ISOTRETINOIN (PRR 55.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Isotretinoin	504	55.9	56.5
Glycerin, Lidocaine	102	36.2	36.4
Docosanol	104	35.3	35.5
Quinine	13	7.4	7.4
Lapatinib	23	7.2	7.2
Tretinoin	12	7.2	7.2
Loperamide Hydrochloride Oral	14	6.7	6.7
Lanreotide Acetate	10	6.2	6.2
Peginterferon Alfa-2A	68	6.2	6.2
Crisaborole	11	5.6	5.6
Losartan Potassium And Hydrochlorothiazide	13	5.4	5.5
Loperamide Hcl	14	5.3	5.3
Felodipine Extended-Release Tablets	11	4.7	4.7
Felodipine	11	4.7	4.7
Everolimus	47	4.5	4.5
Epoprostenol	12	4.5	4.5
Sunitinib Malate	35	4.3	4.4
Ribavirin	57	4.3	4.3
Fexofenadine	14	4.1	4.1
Cetuximab	26	4.0	4.0
Valsartan And Hydrochlorothiazide	11	3.9	3.9
Oxybutynin Chloride	7	3.9	3.9
Zinc	19	3.8	3.8
Zinc Chloride	19	3.7	3.7
Zinc Gluconate	20	3.7	3.7
Cabozantinib	35	3.6	3.6
Buspirone Hydrochloride	8	3.5	3.5
Niraparib	16	3.5	3.5
Panitumumab	11	3.4	3.4
0Xygen	34	3.4	3.4
Oxygen	34	3.4	3.4
Dexamethasone Sodium Phosphate	7	3.3	3.3
Rucaparib	6	3.3	3.3
Loperamide Hydrochloride	30	3.3	3.3
Raloxifene Hydrochloride	9	3.0	3.0
Letrozole Tablets	29	2.9	2.9
Voriconazole	18	2.9	2.9
Palbociclib	55	2.8	2.8
Avapritinib	7	2.8	2.8
Umeclidinium	5	2.7	2.7
Irinotecan Hydrochloride	7	2.6	2.6
Ibuprofen Tablets, Coated	23	2.6	2.6
Pirfenidone	22	2.6	2.6
Multivitamin	27	2.6	2.6
Ibuprofen Sodium	23	2.6	2.6
Armodafinil	11	2.5	2.5
Regorafenib	6	2.5	2.5
Axitinib	10	2.5	2.5
Fexofenadine Hydrochloride	11	2.5	2.5
Dupilumab	235	2.4	2.4
Azelastine	9	2.4	2.4
Osimertinib	16	2.4	2.4
Lifitegrast	8	2.4	2.4
Oxybutynin	14	2.3	2.3
Sulfur	4	2.3	2.3
Capecitabine	43	2.3	2.3
Bimekizumab	10	2.3	2.3
Alpelisib	4	2.2	2.2
Fluticasone Propionate And Salmeterol	19	2.2	2.2
Teriflunomide	20	2.2	2.2
Gefitinib	4	2.2	2.2
Secukinumab	69	2.1	2.1
Selexipag	11	2.1	2.1
Relugolix	10	2.1	2.1
Diroximel Fumarate	5	2.0	2.0
Trametinib	10	2.0	2.0
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	17	2.0	2.0
Oseltamivir Phosphate	10	2.0	2.0
Desvenlafaxine Succinate	11	2.0	2.0
Asfotase Alfa	4	1.9	1.9
Sodium Oxybate	25	1.8	1.8
Loratadine And Pseudoephedrine Sulfate	3	1.8	1.8
Fesoterodine Fumarate	4	1.8	1.8
Umeclidinium Bromide And Vilanterol Trifenatate	6	1.7	1.7
Sarilumab	9	1.7	1.7
Apalutamide	4	1.7	1.7
Abaloparatide	10	1.7	1.7
Brivaracetam	3	1.6	1.6
Eptinezumab-Jjmr	3	1.6	1.6
Adapalene	59	1.6	1.6
Varenicline Tartrate	25	1.5	1.5
Sofosbuvir	6	1.5	1.5
Canagliflozin	8	1.3	1.3
Dornase Alfa	5	1.2	1.2
Guselkumab	9	1.2	1.2
Nemolizumab-Ilto	3	1.1	1.1
Ledipasvir And Sofosbuvir	4	1.0	1.0
Alirocumab	5	1.0	1.0
Valbenazine	5	1.0	1.0
Orlistat	5	0.9	0.9
Salicylic Acid	10	0.9	0.9
Galcanezumab-Gnlm	5	0.8	0.8
Evolocumab	22	0.7	0.7
Nirmatrelvir And Ritonavir	7	0.6	0.6
Tirzepatide	20	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.